Mark A. Lampert, Ph.D.

Associate

+1 202 408 4030 +1 202 408 4030
mark.lampert@finnegan.com mark.lampert@finnegan.com

901 New York Avenue, NW
Washington, DC 20001-4413

vCard

Show Mark's work in

Mark Lampert, Ph.D., focuses on patent litigation in a variety of technical areas, with an emphasis on the pharmaceutical and biotechnology spaces. He also prosecutes patent portfolios and provides client counseling related to biomedical technologies.

Mark contributes to various litigation stages and is actively involved in all phases, including pre-litigation counseling and discovery. Mark also researches and assesses complex legal issues as well as assists with drafting expert reports.

While in law school, Mark was a Sidney B. Williams, Jr. Scholar. The scholarship program provides guidance to those in underrepresented groups who show a commitment to the patent law profession. As a scholar, he met federal judges and US Patent and Trademark Office (USPTO) patent examiners and attended intellectual property workshops. Mark was also a member of the Duke Law & Contemporary Problems Journal.

Mark is committed to pro bono matters. He assists veterans seeking discharge upgrades before the Board for Corrections of Naval Records through brief drafting and counseling.

Et Cetera

Staff editor, Duke Law & Contemporary Problems, 2021-2023.
Recipient, Sidney B. Williams, Jr. Scholar, 2020-2023.
Coauthor. “Deciphering functional roles and interplay between Beclin1 and Beclin2 in autophagosome formation and mitophagy,” Science Signaling, 2023.
Coauthor. “Aging is associated with a decline in Atg9b-mediated autophagosome formation and appearance of enlarged mitochondria in the hear,” Aging Cell, 2020.
Coauthor. “Nuclear Parkin activates the ERRα Transcriptional Program and Drives Widespread Changes in Gene Expression Following Hypoxia,” Scientific Reports, 2020.
Coauthor. “Mitochondria and autophagy in adult stem cells: proliferate or differentiate,” Journal of Muscle Research and Cell Motility, 2019.
Coauthor. “BNIP3L/NIX and FUNDC1-mediated mitophagy is required for mitochondrial network remodeling during cardiac progenitor cell differentiation,” Autophagy, 2019.
Coauthor. “Balancing Autophagy for a Healthy Heart,” Current Opinion in Physiology, 2018.

Experience

Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof

Representing respondent Wacker Biotech GmbH in a rare section 337 ITC investigation involving drug products containing C-type natriuretic peptide variants.

337-TA-1447, ITC, Judge Cheney

Representing plaintiff Pioneer in a district court patent infringement litigation involving methods for producing doubled haploid maize plants.

1:22-cv-01280, D. Del.

Representing defendant Corteva in a Delaware state court action for breach of contract arising out of a patent cross-license agreement relating to Agrobacterium-mediated plant transformation and transgenic seeds.

N22C-07-168, Delaware Superior Court, Complex Commercial Litigation Division

Representing plaintiff Corteva Agriscience in a district court patent infringement litigation involving transgenic plants and plant cells that produce enzymes conferring herbicide resistance.

1:22-cv-01046, D. Del., Judge Williams

Arvinas Operations, Inc. et al. v. Qian et al.

Defending Accutar Biotechnology, Inc. in a trade secret lawsuit brought by Arvinas regarding alleged trade secrets concerning breast cancer therapies.

3:22-cv-00717, D. Conn., Judges Chatigny, Richardson